GPC3 and hepatocellular carcinoma: A phase I trial in advanced HCC has demonstrated that GPC3 peptide vaccine-induced GPC3-specific CTLs that could infiltrate into the HCC tissues, leading to improved OS induced by GPC3-based vaccine in advanced HCC (Tsuchiya et al., 2017).